NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes

Maria Soledad Sosa, Falguni Parikh, Alexandre Gaspar Maia, Yeriel Estrada, Almudena Bosch, Paloma Bragado, Esther Ekpin, Ajish George, Yang Zheng, Hung Ming Lam, Colm Morrissey, Chi Yeh Chung, Eduardo F. Farias, Emily Bernstein, Julio A. Aguirre-Ghiso

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Metastases can originate from disseminated tumour cells (DTCs), which may be dormant for years before reactivation. Here we find that the orphan nuclear receptor NR2F1 is epigenetically upregulated in experimental head and neck squamous cell carcinoma (HNSCC) dormancy models and in DTCs from prostate cancer patients carrying dormant disease for 7-18 years. NR2F1-dependent dormancy is recapitulated by a co-treatment with the DNA-demethylating agent 5-Aza-C and retinoic acid across various cancer types. NR2F1-induced quiescence is dependent on SOX9, RARβ and CDK inhibitors. Intriguingly, NR2F1 induces global chromatin repression and the pluripotency gene NANOG, which contributes to dormancy of DTCs in the bone marrow. When NR2F1 is blocked in vivo, growth arrest or survival of dormant DTCs is interrupted in different organs. We conclude that NR2F1 is a critical node in dormancy induction and maintenance by integrating epigenetic programmes of quiescence and survival in DTCs.

Original languageEnglish (US)
Article number7170
JournalNature Communications
Volume6
DOIs
StatePublished - Jan 30 2015
Externally publishedYes

Fingerprint

Tumors
tumors
Cells
cancer
Neoplasms
COUP Transcription Factor I
Orphan Nuclear Receptors
chromatin
bone marrow
metastasis
Tretinoin
Survival
organs
genes
inhibitors
maintenance
Chromatin
induction
Bone
Epigenomics

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Sosa, M. S., Parikh, F., Gaspar Maia, A., Estrada, Y., Bosch, A., Bragado, P., ... Aguirre-Ghiso, J. A. (2015). NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes. Nature Communications, 6, [7170]. https://doi.org/10.1038/ncomms7170

NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes. / Sosa, Maria Soledad; Parikh, Falguni; Gaspar Maia, Alexandre; Estrada, Yeriel; Bosch, Almudena; Bragado, Paloma; Ekpin, Esther; George, Ajish; Zheng, Yang; Lam, Hung Ming; Morrissey, Colm; Chung, Chi Yeh; Farias, Eduardo F.; Bernstein, Emily; Aguirre-Ghiso, Julio A.

In: Nature Communications, Vol. 6, 7170, 30.01.2015.

Research output: Contribution to journalArticle

Sosa, MS, Parikh, F, Gaspar Maia, A, Estrada, Y, Bosch, A, Bragado, P, Ekpin, E, George, A, Zheng, Y, Lam, HM, Morrissey, C, Chung, CY, Farias, EF, Bernstein, E & Aguirre-Ghiso, JA 2015, 'NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes', Nature Communications, vol. 6, 7170. https://doi.org/10.1038/ncomms7170
Sosa, Maria Soledad ; Parikh, Falguni ; Gaspar Maia, Alexandre ; Estrada, Yeriel ; Bosch, Almudena ; Bragado, Paloma ; Ekpin, Esther ; George, Ajish ; Zheng, Yang ; Lam, Hung Ming ; Morrissey, Colm ; Chung, Chi Yeh ; Farias, Eduardo F. ; Bernstein, Emily ; Aguirre-Ghiso, Julio A. / NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes. In: Nature Communications. 2015 ; Vol. 6.
@article{d7a1569aa3694a04a0214f76297490d2,
title = "NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes",
abstract = "Metastases can originate from disseminated tumour cells (DTCs), which may be dormant for years before reactivation. Here we find that the orphan nuclear receptor NR2F1 is epigenetically upregulated in experimental head and neck squamous cell carcinoma (HNSCC) dormancy models and in DTCs from prostate cancer patients carrying dormant disease for 7-18 years. NR2F1-dependent dormancy is recapitulated by a co-treatment with the DNA-demethylating agent 5-Aza-C and retinoic acid across various cancer types. NR2F1-induced quiescence is dependent on SOX9, RARβ and CDK inhibitors. Intriguingly, NR2F1 induces global chromatin repression and the pluripotency gene NANOG, which contributes to dormancy of DTCs in the bone marrow. When NR2F1 is blocked in vivo, growth arrest or survival of dormant DTCs is interrupted in different organs. We conclude that NR2F1 is a critical node in dormancy induction and maintenance by integrating epigenetic programmes of quiescence and survival in DTCs.",
author = "Sosa, {Maria Soledad} and Falguni Parikh and {Gaspar Maia}, Alexandre and Yeriel Estrada and Almudena Bosch and Paloma Bragado and Esther Ekpin and Ajish George and Yang Zheng and Lam, {Hung Ming} and Colm Morrissey and Chung, {Chi Yeh} and Farias, {Eduardo F.} and Emily Bernstein and Aguirre-Ghiso, {Julio A.}",
year = "2015",
month = "1",
day = "30",
doi = "10.1038/ncomms7170",
language = "English (US)",
volume = "6",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes

AU - Sosa, Maria Soledad

AU - Parikh, Falguni

AU - Gaspar Maia, Alexandre

AU - Estrada, Yeriel

AU - Bosch, Almudena

AU - Bragado, Paloma

AU - Ekpin, Esther

AU - George, Ajish

AU - Zheng, Yang

AU - Lam, Hung Ming

AU - Morrissey, Colm

AU - Chung, Chi Yeh

AU - Farias, Eduardo F.

AU - Bernstein, Emily

AU - Aguirre-Ghiso, Julio A.

PY - 2015/1/30

Y1 - 2015/1/30

N2 - Metastases can originate from disseminated tumour cells (DTCs), which may be dormant for years before reactivation. Here we find that the orphan nuclear receptor NR2F1 is epigenetically upregulated in experimental head and neck squamous cell carcinoma (HNSCC) dormancy models and in DTCs from prostate cancer patients carrying dormant disease for 7-18 years. NR2F1-dependent dormancy is recapitulated by a co-treatment with the DNA-demethylating agent 5-Aza-C and retinoic acid across various cancer types. NR2F1-induced quiescence is dependent on SOX9, RARβ and CDK inhibitors. Intriguingly, NR2F1 induces global chromatin repression and the pluripotency gene NANOG, which contributes to dormancy of DTCs in the bone marrow. When NR2F1 is blocked in vivo, growth arrest or survival of dormant DTCs is interrupted in different organs. We conclude that NR2F1 is a critical node in dormancy induction and maintenance by integrating epigenetic programmes of quiescence and survival in DTCs.

AB - Metastases can originate from disseminated tumour cells (DTCs), which may be dormant for years before reactivation. Here we find that the orphan nuclear receptor NR2F1 is epigenetically upregulated in experimental head and neck squamous cell carcinoma (HNSCC) dormancy models and in DTCs from prostate cancer patients carrying dormant disease for 7-18 years. NR2F1-dependent dormancy is recapitulated by a co-treatment with the DNA-demethylating agent 5-Aza-C and retinoic acid across various cancer types. NR2F1-induced quiescence is dependent on SOX9, RARβ and CDK inhibitors. Intriguingly, NR2F1 induces global chromatin repression and the pluripotency gene NANOG, which contributes to dormancy of DTCs in the bone marrow. When NR2F1 is blocked in vivo, growth arrest or survival of dormant DTCs is interrupted in different organs. We conclude that NR2F1 is a critical node in dormancy induction and maintenance by integrating epigenetic programmes of quiescence and survival in DTCs.

UR - http://www.scopus.com/inward/record.url?scp=84938626001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938626001&partnerID=8YFLogxK

U2 - 10.1038/ncomms7170

DO - 10.1038/ncomms7170

M3 - Article

C2 - 25636082

AN - SCOPUS:84938626001

VL - 6

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 7170

ER -